NK cell count as predictor of clinical response in patients with rheumatoid arthritis treated with rituximab [Corrigendum].
- Published in:
- 2013
- Publication type:
- Correction Notice
Works in Biologics: Targets & Therapy, 2013, Vol 7
Results: 26
1
2
Optimizing therapeutics in the management of patients with multiple sclerosis: a review of drug efficacy, dosing, and mechanisms of action.
- Published in:
- Biologics: Targets & Therapy, 2013, v. 7, p. 247, doi. 10.2147/BTT.S53007
- By:
- Publication type:
- Article
3
Immunization of rabbits with synthetic peptides derived from a highly conserved β-sheet epitope region underneath the receptor binding site of influenza A virus.
- Published in:
- Biologics: Targets & Therapy, 2013, v. 7, p. 233, doi. 10.2147/BTT.S50870
- By:
- Publication type:
- Article
4
Lessons learned from peginesatide in the treatment of anemia associated with chronic kidney disease in patients on dialysis.
- Published in:
- Biologics: Targets & Therapy, 2013, v. 7, p. 243, doi. 10.2147/BTT.S34935
- By:
- Publication type:
- Article
5
CORRIGENDUM.
- Published in:
- 2013
- Publication type:
- Correction Notice
6
Efficacy of intensity-modulated radiotherapy combined with chemotherapy or surgery in locally advanced squamous cell carcinoma of the head-and-neck.
- Published in:
- Biologics: Targets & Therapy, 2013, v. 7, p. 223, doi. 10.2147/BTT.S48664
- By:
- Publication type:
- Article
7
Everolimus in the treatment of subependymal giant cell astrocytomas, angiomyolipomas, and pulmonary and skin lesions associated with tuberous sclerosis complex.
- Published in:
- Biologics: Targets & Therapy, 2013, v. 7, p. 211, doi. 10.2147/BTT.S25095
- By:
- Publication type:
- Article
8
Cross-reactivity of human monoclonal antibodies generated with peripheral blood lymphocytes from dengue patients with Japanese encephalitis virus.
- Published in:
- Biologics: Targets & Therapy, 2013, v. 7, p. 175, doi. 10.2147/BTT.S47438
- By:
- Publication type:
- Article
9
Treatment and management of myelofibrosis in the era of JAK inhibitors.
- Published in:
- Biologics: Targets & Therapy, 2013, v. 7, p. 189, doi. 10.2147/BTT.S34942
- By:
- Publication type:
- Article
10
Erythropoiesis stimulating agents: approaches to modulate activity.
- Published in:
- Biologics: Targets & Therapy, 2013, v. 7, p. 161, doi. 10.2147/BTT.S45971
- By:
- Publication type:
- Article
11
A novel platinum chromium everolimus-eluting stent for the treatment of coronary artery disease.
- Published in:
- Biologics: Targets & Therapy, 2013, v. 7, p. 149, doi. 10.2147/BTT.S34939
- By:
- Publication type:
- Article
12
Tivozanib in the treatment of renal cell carcinoma.
- Published in:
- Biologics: Targets & Therapy, 2013, v. 7, p. 139, doi. 10.2147/BTT.S32958
- By:
- Publication type:
- Article
13
PEGylated interferon beta-Ia in the treatment of multiple sclerosis - an update.
- Published in:
- Biologics: Targets & Therapy, 2013, v. 7, p. 131, doi. 10.2147/BTT.S29948
- By:
- Publication type:
- Article
14
New and emerging treatments for ulcerative colitis: a focus on vedolizumab.
- Published in:
- Biologics: Targets & Therapy, 2013, v. 7, p. 123, doi. 10.2147/BTT.S30416
- By:
- Publication type:
- Article
15
Bosutinib in the management of chronic myelogenous leukemia.
- Published in:
- Biologics: Targets & Therapy, 2013, v. 7, p. 115, doi. 10.2147/BTT.S30182
- By:
- Publication type:
- Article
16
Hereditary angioedema: epidemiology, management, and role of icatibant.
- Published in:
- Biologics: Targets & Therapy, 2013, v. 7, p. 103, doi. 10.2147/BTT.S27566
- By:
- Publication type:
- Article
17
Cetuximab: its unique place in head and neck cancer treatment.
- Published in:
- Biologics: Targets & Therapy, 2013, v. 7, p. 77, doi. 10.2147/BTT.S43628
- By:
- Publication type:
- Article
18
Clinical use of crizotinib for the treatment of non-small cell lung cancer.
- Published in:
- Biologics: Targets & Therapy, 2013, v. 7, p. 91, doi. 10.2147/BTT.S29026
- By:
- Publication type:
- Article
19
Duration of remission after halving of the etanercept dose in patients with ankylosing spondylitis: a randomized, prospective, long-term, follow-up study.
- Published in:
- Biologics: Targets & Therapy, 2013, v. 7, p. 1, doi. 10.2147/BTT.S31474
- By:
- Publication type:
- Article
20
Focus on the potential role of ficlatuzumab in the treatment of non-small cell lung cancer.
- Published in:
- Biologics: Targets & Therapy, 2013, v. 7, p. 61, doi. 10.2147/BTT.S28908
- By:
- Publication type:
- Article
21
Histone deacetylase inhibitors (HDACIs): multitargeted anticancer agents.
- Published in:
- Biologics: Targets & Therapy, 2013, v. 7, p. 47, doi. 10.2147/BTT.S29965
- By:
- Publication type:
- Article
22
Critical appraisal of axitinib in the treatment of advanced renal cell carcinoma.
- Published in:
- Biologics: Targets & Therapy, 2013, v. 7, p. 39, doi. 10.2147/BTT.S25862
- By:
- Publication type:
- Article
23
Treatment of hemophilia B: focus on recombinant factor IX.
- Published in:
- Biologics: Targets & Therapy, 2013, v. 7, p. 33, doi. 10.2147/BTT.S31582
- By:
- Publication type:
- Article
24
Factors correlated with improvement of endothelial dysfunction during rituximab therapy in patients with rheumatoid arthritis.
- Published in:
- Biologics: Targets & Therapy, 2013, v. 7, p. 69, doi. 10.2147/BTT.S39182
- By:
- Publication type:
- Article
25
Profile of reslizumab in eosinophilic disease and its potential in the treatment of poorly controlled eosinophilic asthma.
- Published in:
- Biologics: Targets & Therapy, 2013, v. 7, p. 7, doi. 10.2147/BTT.S30133
- By:
- Publication type:
- Article
26
Relapsed and refractory lymphoid neoplasms and multiple myeloma with a focus on carfilzomib.
- Published in:
- Biologics: Targets & Therapy, 2013, v. 7, p. 13, doi. 10.2147/BTT.S24580
- By:
- Publication type:
- Article